Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 126Melanoma 92Neoplasms 82Colorectal Neoplasms 62Squamous Cell Carcinoma of Head and Neck 61Neoplasm Metastasis 59Triple Negative Breast Neoplasms 51Carcinoma, Renal Cell 47Breast Neoplasms 39Lung Neoplasms 37Ovarian Neoplasms 32Pancreatic Neoplasms 30Head and Neck Neoplasms 29Stomach Neoplasms 28Urinary Bladder Neoplasms 26Carcinoma, Transitional Cell 26Endometrial Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 23Uterine Cervical Neoplasms 21Carcinoma, Hepatocellular 18Recurrence 15Esophageal Neoplasms 15Prostatic Neoplasms 14Lymphoma 14Small Cell Lung Carcinoma 12Carcinoma, Squamous Cell 12Kidney Neoplasms 11Cholangiocarcinoma 11Advanced Solid Tumor 11Solid Tumor 10

Interventions

Temozolomide 38Radiotherapy 17Filgrastim 14Surgical Procedures, Operative 11Irinotecan 11Carmustine 10Carboplatin 10Radiation 9O(6)-benzylguanine 9Magnetic Resonance Spectroscopy 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7Flucytosine 7sargramostim 6Radiotherapy, Intensity-Modulated 5Peripheral Blood Stem Cell Transplantation 5Etoposide 5Erlotinib Hydrochloride 5Bevacizumab 5vocimagene amiretrorepvec 4Vorinostat 4Thiotepa 4Melphalan 4Lenalidomide 4IL13-PE38 4Genetic Therapy 4Cyclophosphamide 4Chemotherapy, Adjuvant 4Busulfan 4lonafarnib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Astrocytoma × pembrolizumab × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡